Decades of research pay off for MS patients

12/27/2011 | New York Times (tiered subscription model), The

After decades of research with few breakthroughs, eight multiple sclerosis drugs are slowing disease progression and helping patients manage their conditions. Though first-generation immune-suppressing drugs are still in use, newer drugs target specific molecules associated with MS, and others that prevent nerve damage are in late stages of development. "We have a disease that's gone from having no treatments 20 years ago to having multiple treatment options," said National Multiple Sclerosis Society Chief Research Officer Dr. Timothy Coetzee.

View Full Article in:

New York Times (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations